GRWD0715

GRWD0715 is a small molecule inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1), developed by Grey Wolf Therapeutics. It is designed as an oral therapy for autoimmune diseases, with axial spondyloarthritis as a lead indication in preclinical development. The drug works by inhibiting ERAP1, a key enzyme involved in the antigen presentation pathway that shapes the repertoire of peptides displayed on major histocompatibility complex (MHC) class I molecules. By modulating antigen presentation, GRWD0715 aims to prevent the generation and display of disease-causing autoantigens, thereby reducing pathogenic immune responses and preventing inflammation at its source rather than suppressing downstream inflammatory mediators[1][2][4][8]. This approach represents a novel strategy distinct from traditional immunosuppressive therapies.